Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

PHASE1CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

September 30, 2010

Study Completion Date

March 31, 2013

Conditions
Post-Traumatic Stress Disorder
Interventions
BEHAVIORAL

Cognitive Behavioral Therapy

Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.

BEHAVIORAL

Motivational Interviewing

Motivational interviewing is designed to address alcohol and drug use.

DRUG

FDA-Approved Anti-Anxiety Medications

Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.

BEHAVIORAL

Standard Care Control

Standard care control includes the usual treatment for injured trauma survivors.

Trial Locations (1)

98104

Harborview Medical Center, Seattle

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Washington

OTHER

NCT00270959 - Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury | Biotech Hunter | Biotech Hunter